Eli Lilly is the leader in the GLP-1 space, but heres another GLP-1 stock and a medical device maker to…
The market for obesity drugs may soon reach almost $100 billion.…
These are the stocks posting the largest moves in premarket trading.…
For years, the trillion-dollar club was an exclusive playground for tech giants, with their big spends and even bigger revenues.…
Hims & Hers Health, Eli Lilly, and Novo Nordisk shares all slid Thursday after Hims & Hers said it would…
The stock price has climbed in the triple digits over three years.…
STORY: Shares of Novo Nordisk plunged again on Thursday after online telehealth firm Hims & Hers said it will offer…
Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.…
Hims & Hers has a GLP-1 weight loss pill -- and its the cheapest one out there.…
Für das 4. Quartal 2025 wurde ein Umsatzsprung von 43 % auf 19,3 Mrd. USD gemeldet. Die Verkäufe von Mounjaro und Zepbound verdoppeln sich nahezu und treiben…
Eli Lilly (LLY) ist nicht mehr nur ein Pharmaunternehmen, es ist eine unaufhaltsame Wachstumsmaschine. Während die Konkurrenz strauchelt, liefert der…
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.…
Combined sales for the companys blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.…
The split in outlook underscores Lillys strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer…
Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." AI…
Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.…
Image source: The Motley Fool.DateFeb. 4, 2026 at 10 a.m. ETCall participantsChair and Chief Executive Officer — David RicksChief Financial…
Eli Lilly Chief Financial Officer Lucas Montarce says their weight loss pill is on track to launch in the US in…
On Wednesday morning, the pharmaceutical giant with headquarters in Indianapolis, Ind. announced its financial results for the fourth quarter of…
These are the stocks posting the largest moves in premarket trading.…
INDIANAPOLIS (dpa-AFX) - Anders als Konkurrent Novo Nordisk rechnet der US-Pharmahersteller Lilly auch in…
Eli Lillys full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and…
Eli Lilly sees 2026 profit above estimates on weight?loss drug demand…
Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as…
Eli Lilly and Co (NYSE:LLY) shares surged 9.5% in Wednesday morning trading after the drugmaker posted fourth-quarter results that topped…
Bank says latest CagriSema results meet expectations, with investor focus shifting to head-to-head data against Eli Lilly’s tirzepatide. Novo Nordisk...…
The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade…
AMD, Alphabet and Amazon are among the heavyweight companies reporting earnings in the week ahead.…
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.27% move from the…
Google, AMD, Eli Lilly, Amazon and Palantir headline another big earnings week.…
Lilly CEO Dave Ricks is confident in the ability of the companys pill to compete and is preparing for a…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
The plant will help make Lillys experimental drug called retatrutide, which has shown the highest weight loss seen to date…
Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in…
The target action date for orforglipron is now April 10.…
Is there another beat-and-raise in the pharmaceutical giants near future?…
U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and…
U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on…
Eli Lilly and Co (NYSE:LLY) announced that it has entered a strategic global research collaboration and licensing agreement with Seamless…
Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine…
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks…
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical…
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks…
Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage wont last forever.…
…
Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -2.12% move from the prior day.…
Eli Lillys valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.…
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in…
Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may…
Is the Magnificent 7 finished? NVDA shines while Tesla struggles and Eli Lilly surges, as Zacks Market Edge debates who…